Pentosan Polysulfate
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Pentosan Polysulfate: Primary release disorder of platelets
One-Sentence Summary
Pentosan polysulfate is a heparin-like sulfated polysaccharide, originally used to treat interstitial cystitis. The TxGNN model predicts it may be effective for primary release disorder of platelets, but no clinical trials and no publications currently support this prediction. The prediction rests on the model score alone, and the available data point to a bleeding-risk concern rather than a therapeutic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 0.9971 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pentosan polysulfate is a heparin-like sulfated polysaccharide with weak anticoagulant activity. It is established in interstitial cystitis, but no mechanism has been verified that would apply to a platelet disorder.
The connection to the new indication is weak. A platelet release (secretion) defect involves impaired granule release by platelets. A drug with anticoagulant properties would be expected to worsen, not improve, a bleeding tendency. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The other two top predictions, Glanzmann thrombasthenia (0.9965) and pseudo-von Willebrand disease (0.9962), also have no supporting trials or literature. Pseudo-von Willebrand disease has a theoretical link, since sulfated polysaccharides can interact with VWF/GPIb binding. However, the direction of any effect is unknown and would need preclinical validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 176373 | Pentossan 100 Capsule (AMPS Biotech Pvt Ltd) | Bottle of 90 capsules | – |
| 34200 | Cystopen Capsule (Sun Pharmaceutical Industries Ltd) | Strip of 10 capsules | – |
| 34943 | Comfora Capsule (Swati Spentose Pvt Ltd) | Strip of 10 capsules | – |
| 178096 | Pentossan 100 Capsule (AMPS Biotech Pvt Ltd) | Strip of 10 capsules | – |
| 84495 | For-IC Capsule (Cipla Ltd) | Strip of 10 capsules | – |
All six registrations are single-ingredient oral capsules and all are valid. A sixth registration (36228, Comfora Capsule, bottle of 90 capsules, Swati Spentose Pvt Ltd) is not shown in the table above. The approved indication text is not available in the compiled data.
Safety Considerations
- Contraindications (from drug-disease associations in the knowledge graph, not label text): liver disease, gallbladder disease, thrombocytopenia, blood coagulation disease, hemophilia, heparin-induced thrombocytopenia.
- Drug Interactions: 58 interactions recorded. The 20 retrieved are all Moderate and mostly involve agents affecting coagulation or platelet function, which suggests additive bleeding risk. Examples:
- Antiplatelet agents: acetylsalicylic acid, clopidogrel, cilostazol, dipyridamole, abciximab, cangrelor
- Anticoagulants: warfarin, apixaban, edoxaban, betrixaban, dalteparin, bivalirudin, antithrombin III
- Thrombolytics: alteplase, anistreplase
- Others: defibrotide, caplacizumab, ibritumomab tiuxetan, tositumomab
The knowledge-graph contraindications (coagulation disorders, hemophilia, thrombocytopenia) overlap directly with the bleeding-related conditions proposed as new indications. Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (Evidence Level L5), with no trials or publications. The drug’s anticoagulant properties and the contraindication signals for coagulation disorders make a benefit in a platelet release disorder mechanistically implausible and potentially harmful.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulatory source (currently a blocking gap for safety screening)
- Mechanism of action data (e.g., from DrugBank)
- Preclinical validation, such as platelet function and VWF/GPIb binding assays, particularly for pseudo-von Willebrand disease
- A review of whether the prediction only reflects similarities the TxGNN model (deep learning) learned between related diseases, not biological evidence, before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.